SFPM 2024 October Virtual Monthly Seminar featuring our co-founder Kyuson Yun, PhD

Join us at this month's virtual seminar as our co-founder Kyuson Yun, PhD will present "E-slice: TME-intact 3D culture platform for functional precision medicine and immunotherapy evaluation"

Learn about our proprietary E-slice technology that can preserve a tumor TME for improved precision medicine and immune response.

SEMINAR DETAILS

Wednesday, October 9, 2024 @ 12:00 PM EDT

Meeting URL: zoom.us

Meeting ID: 828 5622 5783 | Password: 027718

To learn more, please visit: https://sfpm.membershiptoolkit.com/newsletter/05026-20241007110012-014264800-1977779962

See you there on October 9th!

Join Us at the 10x Genomics User Group Meeting!

We are excited to share that Kyuson Yun, co-founder of Empiri, will be presenting at the 10x Genomics User Group Meeting. This is a fantastic opportunity to learn about our high-quality, end-to-end single cell RNA sequencing services, from tissue dissociation to bioinformatics analysis.

Event Details:

Date: May 21, 2024

Location: Westin Houston Medical Center, Houston, TX

Kyuson’s talk “Elucidating mechanisms of action of a novel immune modulator through single cell RNA-sequencing” will be one of the featured presentations in the morning. Come to our table and talk with us about how Empiri's comprehensive approach can provide deeper insights into tumor biology and accelerate your research. Don't miss this chance to connect with industry leaders and explore the latest advancements in single cell RNA sequencing.

Register now at https://bit.ly/3JhrLjE

Stay tuned for more updates and follow us on LinkedIn and Twitter!

Our store-front at Scientist.com

EMPIRI's E-slice 3D tumor culture platform for real-time evaluation of therapeutic candidates can now be accessed through our store-front at Scienist.Com for expedited study quoting and contracting. https://app.scientist.com/providers/empiri-inc

E-slice enables efficacy, target validation, and MOA studies, including chemo, targeted, immune, virotherapy, cell-based and combinations while maintaining the native TME cell-cell and cell-matrix interactions unique to each patient’s tumor. Results are availalable in a clinically-actionable time frame of 4-8 days with tissue viability out to 28+ days in many cases.

Contact us if there is interest in a detailed discussion around how E-slice can be used to enhance both preclinical drug discovery and development efforts and clinical diagnosis. #cancerresearch #immunotherapy #drugdiscovery #scRNAseq #clinicaltrials #oncology #3dculture #TME #cancerdrugs #ESlice